Current Hematologic Malignancy Reports

Papers
(The TQCC of Current Hematologic Malignancy Reports is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas51
IDH Inhibitors in AML—Promise and Pitfalls33
MRD Assessment in Multiple Myeloma: Progress and Challenges31
Management of Ibrutinib Toxicities: a Practical Guide26
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments21
CAR-T Cell Therapy: the Efficacy and Toxicity Balance21
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib20
Treatment-Free Remission: the New Goal in CML Therapy17
Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia17
Enteropathy-Associated T cell Lymphoma16
Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms15
Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review15
Thrombocytosis and Thrombosis: Is There Really a Correlation?15
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies14
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders14
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia13
Future Directions in Chronic Phase CML Treatment12
Tweeting from the Bench: Twitter and the Physician-Scientist Benefits and Challenges11
Molecular Pathogenesis of Myeloproliferative Neoplasms11
Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches11
Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding11
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities11
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions11
Antibody-Based Treatment Approaches in Multiple Myeloma10
Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma10
Updates in the Diagnosis and Management of AL Amyloidosis10
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms10
Social Media for Hematopathologists: Medical Practice Reinvented—#Hemepath10
Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit9
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?9
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia9
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms9
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)9
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options9
Advances in Supportive Care for Acute Lymphoblastic Leukemia8
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia8
Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies7
Radiogenomics and Its Role in Lymphoma7
Management of Chronic Myeloid Leukemia in Children and Young Adults7
Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?7
The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond7
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra7
BTK Inhibitors in Chronic Lymphocytic Leukemia7
MRD in ALL: Optimization and Innovations7
Treatment of Aggressive B Cell Lymphomas: Updates in 20197
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management7
0.034043788909912